Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease

Completed · Phase 2

Conditions studied: Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy

In brief

Levetiracetam (Keppra) is used to treat partial onset seizures. Its biological effects suggest it might also be useful in treating 3 aspects of human motor neuron diseases (MNDs) for which no effective therapy exists: cramps, spasticity, and disease progression.

Key facts

Study ID

NCT00324454

Run by

Duke University

People needed

20

Starts

2006-05-01

Expected to finish

2008-06-01

Last updated by the study team

2013-06-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with MNDs (ALS, PLS or PMA)who have cramps with average severity 50/100 points, are able to provide informed consent, have normal renal function and are on a stable riluzole dose.

You may not qualify if…

• Pregnancy; unstable medical illness, dementia; drug abuse or non-compliance

Where it is running

• Duke University ALS Clinic - 932 Morreene Road — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.